Pulmonx Corp (NASDAQ:LUNG) — Market Cap & Net Worth
Market Cap & Net Worth: Pulmonx Corp (LUNG)
Pulmonx Corp (NASDAQ:LUNG) has a market capitalization of $83.75 Million ($83.75 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19938 globally and #4554 in its home market, demonstrating a -6.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pulmonx Corp's stock price $1.95 by its total outstanding shares 42948269 (42.95 Million). Also see Pulmonx Corp (LUNG) total assets for a full breakdown of the balance sheet.
Pulmonx Corp Market Cap History: 2020 to 2026
Pulmonx Corp's market capitalization history from 2020 to 2026. Data shows change from $2.96 Billion to $83.75 Million (-39.58% CAGR). Also see cash flow conversion of Pulmonx Corp for how efficiently the company converts equity into cash flow.
Index Memberships
Pulmonx Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #569 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1923 of 3165 |
Weight: Pulmonx Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pulmonx Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pulmonx Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check LUNG share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.05x
Pulmonx Corp's market cap is 1.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.96 Billion | $32.73 Million | -$32.23 Million | 90.56x | N/A |
| 2021 | $1.38 Billion | $48.42 Million | -$48.66 Million | 28.45x | N/A |
| 2022 | $362.05 Million | $53.66 Million | -$58.92 Million | 6.75x | N/A |
| 2023 | $547.59 Million | $68.67 Million | -$60.84 Million | 7.97x | N/A |
| 2024 | $291.62 Million | $83.79 Million | -$56.39 Million | 3.48x | N/A |
| 2025 | $94.92 Million | $90.50 Million | -$54.00 Million | 1.05x | N/A |
Competitor Companies of LUNG by Market Capitalization
Companies near Pulmonx Corp in the global market cap rankings as of September 17, 2026. Review tangible equity quality of Pulmonx Corp to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Pulmonx Corp by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #125 globally with a market cap of $177.99 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #229 globally with a market cap of $109.23 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #125 | Abbott Laboratories | NYSE:ABT | $177.99 Billion | $102.36 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.60 |
| #229 | Stryker Corporation | NYSE:SYK | $109.23 Billion | $284.76 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Pulmonx Corp Historical Marketcap From 2020 to 2026
Between 2020 and today, Pulmonx Corp's market cap moved from $2.96 Billion to $ 83.75 Million, with a yearly change of -39.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $83.75 Million | -11.76% |
| 2025 | $94.92 Million | -67.45% |
| 2024 | $291.62 Million | -46.75% |
| 2023 | $547.59 Million | +51.25% |
| 2022 | $362.05 Million | -73.71% |
| 2021 | $1.38 Billion | -53.54% |
| 2020 | $2.96 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Pulmonx Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $83.75 Million USD |
| MoneyControl | $83.75 Million USD |
| MarketWatch | $83.75 Million USD |
| marketcap.company | $83.75 Million USD |
| Reuters | $83.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ven… Read more